½ÃÀ庸°í¼
»óÇ°ÄÚµå
1558611
¼¼°èÀÇ Àü°Ô³ð ¹× ¿¢¼Ø ½ÃÄö½Ì ½ÃÀå : Á¦Ç°º°, ¿öÅ©Ç÷ο캰, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°, °æÀï ±¸µµ - ºÐ¼®°ú ¿¹Ãø(2024-2033³â)Global Whole Genome and Exome Sequencing Market: Focus on Product, Workflow, Application, End User, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033 |
Àü°Ô³ð ½ÃÄö½º(WGS) ¹× ¿¢¼Ø ½ÃÄö½º(WES)´Â »ý¹° À¯Àü ¹°ÁúÀÇ Á¾ÇÕÀû Çؼ®À» °¡´ÉÇÏ°Ô ÇÏ´Â ÃÖ÷´Ü °Ô³ð ±â¼úÀÔ´Ï´Ù.
WGS´Â ÄÚµå ¿µ¿ª°ú ºñÄÚµå ¿µ¿ªÀ» ¸ðµÎ Æ÷ÇÔÇÏ´Â Àüü À¯ÀüüÀ» ½ÃÄö½ÌÇÏ¿© ¿ÏÀüÇÑ À¯ÀüÀÚ ¼³°èµµ¸¦ Á¦°øÇÕ´Ï´Ù. ¹Ý¸é, WES´Â ¿¢¼Õ ¿µ¿ª(À¯ÀüüÀÇ ´Ü¹éÁúÀ» ¾ÏÈ£ÈÇÏ´Â ºÎºÐ, À¯ÀüüÀÇ ¾à 1-2%¸¦ Â÷ÁöÇÏÁö¸¸ ¾Ë·ÁÁø Áúº´°ú °ü·ÃµÈ º¯ÀÌüÀÇ ´ëºÎºÐÀ» Æ÷ÇÔÇÏ´Â ºÎºÐ)¸¸À» ½ÃÄö½ÌÇÏ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº À¯ÀüÀû º¯ÀÌ, Áúº´ ¸ÞÄ¿´ÏÁò, ÁøÈ »ý¹°Çп¡ ´ëÇÑ Àü·Ê ¾ø´Â ÀλçÀÌÆ®À» Á¦°øÇÔÀ¸·Î½á À¯ÀüüÇп¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ÀÓ»ó Áø´Ü, ¸ÂÃãÇü ÀÇ·á, Á¾¾çÇÐ, Èñ±ÍÁúȯ ¿¬±¸ µî ´Ù¾çÇÑ ºÐ¾ß¿¡ Àû¿ëµÇ¾î ÀÇ·á ¹× »ý¹° ÀÇÇÐ ¿¬±¸¸¦ Å©°Ô ¹ßÀü½ÃÅ°°í ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ±â¼ú °³¼±, ºñ¿ë Àý°¨, ¿ëµµ È®´ë·Î WGS¿Í WES´Â Çö´ë À¯ÀüüÇп¡¼ ÇʼöÀûÀÎ Åø·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.
ÁÖ¿ä ½ÃÀå Åë°è | |
---|---|
¿¹Ãø ±â°£ | 2024-2033³â |
2024³â Æò°¡ | 21¾ï 120¸¸ ´Þ·¯ |
2033³â ¿¹Ãø | 74¾ï 6,760¸¸ ´Þ·¯ |
CAGR | 15.13% |
¼¼°èÀÇ Àü°Ô³ð ¹× ¿¢¼Ø ½ÃÄö½Ì ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 18¾ï 7,380¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀº 2033³â¿¡´Â 74¾ï 6,760¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 15.13%¶ó´Â ÇöÀúÇÑ CAGRÀ» ±â·ÏÇϸç, ´ëÆøÀûÀÎ ¼ºÀåÀÌ Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±Þ°ÝÇÑ Áõ°¡´Â ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í Àü ¼¼°è À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¸¦ ¹Ý¿µÇÏ°í ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·áÀÇ ÇÙ½É ¿ä¼ÒÀÎ À¯ÀüÀÚ °Ë»ç´Â °³ÀÎÀÌ ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ À¯ÀüÀû ¼ÒÀÎÀ» Æò°¡ÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ȯÀÚ¿Í ÀÇ·áÁø¿¡°Ô ¿¹¹æÀû °³ÀÔ°ú ¸ÂÃãÇü Ä¡·á Àü·«¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®À» Á¦°øÇÕ´Ï´Ù. ±â¼úÀÇ ¹ßÀüÀ¸·Î À¯ÀüÀÚ °Ë»çÀÇ Á¤È®¼º°ú Á¢±Ù¼ºÀÌ Áö¼ÓÀûÀ¸·Î Çâ»óµÊ¿¡ µû¶ó ÀÌ ½ÃÀåÀº ÀÇ·á ¼ºñ½º Á¦°ø¿¡ Çõ¸íÀ» ÀÏÀ¸Å°¸ç Àü ¼¼°è¿¡¼ ¿¹¹æ ¹× ¸ÂÃã ÀÇ·áÀÇ ½Ã´ë¸¦ ¿¾î°¡°í ÀÖ½À´Ï´Ù.
Àü°Ô³ð ¹× ¿¢¼Ø ½ÃÄö½Ì ½ÃÀåÀº À¯Àüü ±â¼úÀÇ ¹ßÀü, ½ÃÄö½Ì ºñ¿ëÀÇ °¨¼Ò, Á¤¹ÐÀÇ·á, Áø´Ü, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ À¯Àüü µ¥ÀÌÅÍÀÇ Àû¿ë È®´ë·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇÏ°í ÀÖ½À´Ï´Ù. Àü°Ô³ð ½ÃÄö½Ì(WGS)Àº »ý¹°ÀÇ Àüü À¯ÀüÀÚ ±¸¼º¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ÀλçÀÌÆ®À» Á¦°øÇÕ´Ï´Ù. ¹Ý¸é, Àüü ¿¢¼Ø ½ÃÄö½Ì(WES)Àº À¯ÀüÀÚÀÇ ÄÚµå ¿µ¿ª¿¡ ÃÊÁ¡À» ¸ÂÃß°í Áúº´ ¸ÞÄ¿´ÏÁòÀ» ÀÌÇØÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Á¾¾çÇÐ, Èñ±ÍÁúȯ Áø´Ü, ¾à¹°À¯ÀüüÇÐ ºÐ¾ßÀÇ À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, À¯ÀüüÇÐ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, Á¤ºÎÀÇ À¯Àüü ¿¬±¸ Áö¿ø Á¤Ã¥À¸·Î ÀÎÇØ ½ÃÀåÀÌ È°¼ºÈµÇ°í ÀÖ½À´Ï´Ù. ±× °á°ú, ÀÓ»ó ÇöÀå¿¡¼ WGS¿Í WESÀÇ ÅëÇÕÀÌ ´õ¿í º¸Æíȵǰí ÀÖÀ¸¸ç, Çõ½ÅÀûÀÎ ÇコÄÉ¾î ¼Ö·ç¼Ç°ú ȯÀÚ °á°ú °³¼±ÀÇ ±æÀ» ¿¾î°¡°í ÀÖ½À´Ï´Ù.
¼¼°èÀÇ Àü°Ô³ð ¹× ¿¢¼Ø ½ÃÄö½Ì ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀåÀÇ °³¿ä¿Í Á¦Ç°º°, ¿öÅ©Ç÷ο캰, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ ¹× ½ÃÀå¿¡ Âü¿©ÇÏ´Â ±â¾÷ÀÇ °³¿ä µîÀ» Á¦°øÇÏ°í ÀÖ½À´Ï´Ù.
Introduction of Whole Genome and Exome Sequencing
Whole genome sequencing (WGS) and exome sequencing (WES) are cutting-edge genomic technologies that enable comprehensive analysis of an organism's genetic material. WGS involves sequencing the entire genome, encompassing both coding and non-coding regions, providing a complete genetic blueprint. In contrast, WES focuses on sequencing only the exonic regions, which are the protein-coding parts of the genome, representing about 1-2% of the genome but containing the majority of known disease-related variants. These technologies have revolutionized genomics by offering unprecedented insights into genetic variation, disease mechanisms, and evolutionary biology. Their applications span clinical diagnostics, personalized medicine, oncology, rare disease research, and more, driving significant advancements in healthcare and biomedical research. With continuous technological improvements, decreasing costs, and expanding applications, WGS and WES are becoming indispensable tools in modern genomics.
Market Introduction
KEY MARKET STATISTICS | |
---|---|
Forecast Period | 2024 - 2033 |
2024 Evaluation | $2,101.2 Million |
2033 Forecast | $7,467.6 Million |
CAGR | 15.13% |
The global whole genome and exome sequencing market, initially valued at $1,873.8 million in 2023, is poised for substantial growth, projected to reach $7,467.6 million by 2033, marking a remarkable compound annual growth rate (CAGR) of 15.13%. This surge reflects the escalating demand for personalized medicine and the increasing prevalence of genetic disorders worldwide. Hereditary genetic testing, a pivotal component of precision healthcare, enables individuals to assess their genetic predispositions to various diseases, empowering them and healthcare providers with invaluable insights for proactive intervention and tailored treatment strategies. As advancements in technology continue to enhance the accuracy and accessibility of genetic testing, the market is primed to revolutionize healthcare delivery, ushering in an era of preventive and personalized medicine on a global scale.
The whole genome and exome sequencing market has been experiencing rapid growth driven by advancements in genomic technologies, decreasing sequencing costs, and the expanding applications of genomic data in precision medicine, diagnostics, and personalized healthcare. Whole genome sequencing (WGS) provides comprehensive insights into the entire genetic makeup of an organism. In contrast, whole exome sequencing (WES) focuses on the coding regions of genes, which are crucial for understanding disease mechanisms. The market has been fueled by increasing demand for genetic testing in oncology, rare disease diagnosis, pharmacogenomics, rising investments in genomics research, and favorable government initiatives supporting genetic research. As a result, the integration of WGS and WES in clinical practice is becoming more prevalent, paving the way for innovative healthcare solutions and improved patient outcomes.
Industrial Impact
The industrial impact of the whole genome and exome sequencing market has been profound, significantly influencing various sectors, including healthcare, pharmaceuticals, biotechnology, and research. In healthcare, the adoption of these sequencing technologies has been transforming diagnostics and treatment strategies by enabling precise identification of genetic mutations and tailored therapeutic interventions. This precision medicine approach not only enhances patient care but also reduces healthcare costs by minimizing trial-and-error treatments. In the pharmaceutical industry, whole genome and exome sequencing have been pivotal in drug discovery and development, allowing for the identification of novel drug targets and biomarkers, thereby accelerating the development of targeted therapies. Biotechnology companies are leveraging these technologies to advance research in gene editing, synthetic biology, and agricultural biotechnology, leading to innovations in crop improvement and sustainable agriculture. Moreover, the increasing use of sequencing in academic and clinical research has been driving scientific discoveries and expanding one's understanding of genetic diseases and human biology. Overall, the integration of whole genome and exome sequencing across these industries is fostering innovation, improving efficiency, and opening new avenues for economic growth and development.
Market Segmentation
Segmentation 1: by Product
In the global whole genome and exome sequencing market, as of 2023, the kits segment holds the largest share at 62.83%. This dominance can be attributed to the essential role kits play in the sequencing process, encompassing DNA extraction, library preparation, and target enrichment, which are crucial for accurate and efficient sequencing. Kits are widely adopted due to their ease of use, reliability, and cost-effectiveness, streamlining laboratory workflows and ensuring consistent results. This rapid growth is expected to be driven by the increasing need for advanced bioinformatics tools and data analysis services to handle the vast amounts of data generated by sequencing technologies. Software solutions enhance data management, interpretation, and visualization, while services provide technical support, training, and consultancy, making sequencing data more accessible and actionable for clinical and research applications.
Segmentation 2: by Workflow
Based on workflow, the global whole genome and exome market was led by the WES segment, which held a 64.92% share in 2023. The whole exome sequencing (WES) workflow begins with the extraction, isolation, and purification of DNA from biological samples such as blood or saliva. This is followed by library preparation, where the DNA is fragmented and adaptors are added, and library quantification to ensure accurate DNA concentration. Next, target enrichment involves hybridizing the DNA library with probes that capture the exonic regions, enriching these target sequences. The enriched library is then sequenced using next-generation sequencing (NGS) technology. The resulting data undergoes bioinformatics analysis, where it is aligned to a reference genome, and genetic variations are identified, annotated, and interpreted for their potential impact on gene function and disease association.
Segmentation 3: by Application
Segmentation 4: by End User
In the global whole genome and exome sequencing (WGS and WES) market, as of 2023, the research and academic institutes segment holds the largest share at 39.69%, driven by extensive use in genomic research, significant government funding, and collaborative projects that advance scientific understanding of genetic diseases.
Segmentation 5: by Region
The whole genome and exome market in the North America region is expected to witness a significant growth rate of 14.80% during the forecast period, marked by the increasing prevalence of genetic disorders and the growing demand for personalized medicine and robust government initiatives. However, the Asia-Pacific region is expected to reach $1,784.8 million in 2033 from $372.9 million in 2023, at a CAGR of 17.26% during the forecast period 2024-2033.
Recent Developments in the Whole Genome and Exome Market
Demand - Drivers, Challenges, and Opportunities
Market Demand Drivers:
Growing Applications of Whole Genome and Exome Sequencing in Clinical Diagnostics: The increasing clinical applications of whole genome sequencing (WGS) and whole exome sequencing (WES) are significantly influencing the overall sequencing market. The adoption of WGS in clinical diagnostics for rare diseases is providing a more comprehensive genetic analysis compared to traditional methods. According to a study, "Whole Exome and Genome Sequencing in Mendelian Disorders: A Diagnostic and Health Economic Analysis," published in Nature Journal in August 2022, WGS can detect a broader range of genetic variants, including those in non-coding regions, which are often missed by WES. This comprehensive detection capability improves diagnostic accuracy, thereby enhancing patient care and outcomes.
Market Challenges:
Privacy and Ethical Concerns due to Increased Risk of Security Breaches: Ethical concerns related to privacy, confidentiality, and the return of results are prominent in the context of sequencing and must be addressed during the informed consent process. The method of data storage is crucial in managing privacy risks for participants. Privacy and ethical concerns have become significant challenges in the whole genome and exome sequencing market, especially with the increasing risk of security breaches.
Market Opportunities:
Increasing Usage of Sequencing Methodologies in Emerging Markets: The increasing application of whole genome and whole exome sequencing in developing countries presents a significant growth opportunity for the global market. As these technologies become more affordable and accessible, they are being integrated into healthcare systems in regions that were previously limited by cost and infrastructure. The availability of these advanced sequencing methods allows for the precise diagnosis and treatment of genetic diseases, which can significantly improve healthcare outcomes in these regions. This integration is facilitated by international collaborations and support from global health initiatives, which aim to enhance the capabilities of local healthcare providers.
How can this report add value to an organization?
Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements and emerging applications in genome and exome sequencing, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.
Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.
Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.
Methodology
Key Considerations and Assumptions in Market Engineering and Validation
Primary Research:
The primary sources involve industry experts in whole genome and exome, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.
The key data points taken from the primary sources include:
Secondary Research
Open Sources
The key data points taken from the secondary sources include:
Key Market Players and Competition Synopsis
Profiled companies have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
In 2023, Illumina, Inc. held major share of the whole genome and exome sequencing market, reflecting its leading position and extensive portfolio of advanced sequencing technologies. Thermo Fisher Scientific Inc., Qiagen N.V., Pacific Biosciences (PacBio) and Oxford Nanopore Technologies plc are the other major players with, leveraging its broad range of genomic solutions and strong market presence. The companies are recognized for their innovative sequencing technologies that provide unique capabilities in long-read sequencing and real-time analysis. The competitive landscape, with Illumina leading significantly while other key players continue to innovate and capture niche segments within the market.
Some prominent names established in this market are:
Scope and Definition